Selected research
Industry Research
Epoetin (Eritropoyetin) Industry Research Report 2026
Market perspective
The global Epoetin (Eritropoyetin) market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Epoetin (Eritropoyetin) is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Epoetin (Eritropoyetin) is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Epoetin (Eritropoyetin) is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Epoetin (Eritropoyetin) include Teva Pharmaceutical Industries Ltd, Johnson & Johnson, Roche, Amgen, Ranbaxy Laboratories Ltd, LG Life Sciences Ltd, Intas Pharmaceuticals, Hospira Inc and Epoetin, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Epoetin (Eritropoyetin) market in terms of revenue (US$ million) and, where applicable, sales volume (units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/units) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Epoetin (Eritropoyetin) Market by Company
Teva Pharmaceutical Industries Ltd
Johnson & Johnson
Roche
Amgen
Ranbaxy Laboratories Ltd
LG Life Sciences Ltd
Intas Pharmaceuticals
Hospira Inc
Epoetin
Celltrion, Inc
Biocon
Abcam
Epoetin (Eritropoyetin) Segment by Type
Epoetin-beta
Epoetin-alfa
Darbepoetin Alfa
Epoetin (Eritropoyetin) Segment by Application
Anemia (Cancer and HIV Treatment)
Kidney Disorders (ESRD and Dialysis)
Others (Neural Disease and Wound Healing)
Epoetin (Eritropoyetin) Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Epoetin (Eritropoyetin) market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Epoetin (Eritropoyetin) and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Epoetin (Eritropoyetin).
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Epoetin (Eritropoyetin) manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Epoetin (Eritropoyetin) by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Epoetin (Eritropoyetin) in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Epoetin-beta
- Epoetin-alfa
- Darbepoetin Alfa
Applications
- Anemia (Cancer and HIV Treatment)
- Kidney Disorders (ESRD and Dialysis)
- Others (Neural Disease and Wound Healing)
Companies covered
- Teva Pharmaceutical Industries Ltd
- Johnson & Johnson
- Roche
- Amgen
- Ranbaxy Laboratories Ltd
- LG Life Sciences Ltd
- Intas Pharmaceuticals
- Hospira Inc
- Epoetin
- Celltrion, Inc
- Biocon
- Abcam
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Epoetin (Eritropoyetin) Market Size (2021-2032)
- 2.2.2 Global Epoetin (Eritropoyetin) Sales (2021-2032)
- 2.2.3 Global Epoetin (Eritropoyetin) Market Average Price (2021-2032)
- 2.3 Epoetin (Eritropoyetin) by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 Epoetin-beta
- 2.3.3 Epoetin-alfa
- 2.3.4 Darbepoetin Alfa
- 2.4 Epoetin (Eritropoyetin) by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Anemia (Cancer and HIV Treatment)
- 2.4.3 Kidney Disorders (ESRD and Dialysis)
- 2.4.4 Others (Neural Disease and Wound Healing)
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Epoetin (Eritropoyetin) Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Epoetin (Eritropoyetin) Sales (units) of Manufacturers (2021-2026)
- 3.3 Global Epoetin (Eritropoyetin) Revenue of Manufacturers (2021-2026)
- 3.4 Global Epoetin (Eritropoyetin) Average Price by Manufacturers (2021-2026)
- 3.5 Global Epoetin (Eritropoyetin) Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Epoetin (Eritropoyetin), Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Epoetin (Eritropoyetin), Product Type & Application
- 3.8 Global Manufacturers of Epoetin (Eritropoyetin), Established Date
- 3.9 Global Epoetin (Eritropoyetin) Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Teva Pharmaceutical Industries Ltd
- 4.1.1 Teva Pharmaceutical Industries Ltd Company Information
- 4.1.2 Teva Pharmaceutical Industries Ltd Business Overview
- 4.1.3 Teva Pharmaceutical Industries Ltd Epoetin (Eritropoyetin) Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Teva Pharmaceutical Industries Ltd Epoetin (Eritropoyetin) Product Portfolio
- 4.1.5 Teva Pharmaceutical Industries Ltd Recent Developments
- 4.2 Johnson & Johnson
- 4.2.1 Johnson & Johnson Company Information
- 4.2.2 Johnson & Johnson Business Overview
- 4.2.3 Johnson & Johnson Epoetin (Eritropoyetin) Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Johnson & Johnson Epoetin (Eritropoyetin) Product Portfolio
- 4.2.5 Johnson & Johnson Recent Developments
- 4.3 Roche
- 4.3.1 Roche Company Information
- 4.3.2 Roche Business Overview
- 4.3.3 Roche Epoetin (Eritropoyetin) Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Roche Epoetin (Eritropoyetin) Product Portfolio
- 4.3.5 Roche Recent Developments
- 4.4 Amgen
- 4.4.1 Amgen Company Information
- 4.4.2 Amgen Business Overview
- 4.4.3 Amgen Epoetin (Eritropoyetin) Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 Amgen Epoetin (Eritropoyetin) Product Portfolio
- 4.4.5 Amgen Recent Developments
- 4.5 Ranbaxy Laboratories Ltd
- 4.5.1 Ranbaxy Laboratories Ltd Company Information
- 4.5.2 Ranbaxy Laboratories Ltd Business Overview
- 4.5.3 Ranbaxy Laboratories Ltd Epoetin (Eritropoyetin) Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 Ranbaxy Laboratories Ltd Epoetin (Eritropoyetin) Product Portfolio
- 4.5.5 Ranbaxy Laboratories Ltd Recent Developments
- 4.6 LG Life Sciences Ltd
- 4.6.1 LG Life Sciences Ltd Company Information
- 4.6.2 LG Life Sciences Ltd Business Overview
- 4.6.3 LG Life Sciences Ltd Epoetin (Eritropoyetin) Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 LG Life Sciences Ltd Epoetin (Eritropoyetin) Product Portfolio
- 4.6.5 LG Life Sciences Ltd Recent Developments
- 4.7 Intas Pharmaceuticals
- 4.7.1 Intas Pharmaceuticals Company Information
- 4.7.2 Intas Pharmaceuticals Business Overview
- 4.7.3 Intas Pharmaceuticals Epoetin (Eritropoyetin) Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 Intas Pharmaceuticals Epoetin (Eritropoyetin) Product Portfolio
- 4.7.5 Intas Pharmaceuticals Recent Developments
- 4.8 Hospira Inc
- 4.8.1 Hospira Inc Company Information
- 4.8.2 Hospira Inc Business Overview
- 4.8.3 Hospira Inc Epoetin (Eritropoyetin) Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 Hospira Inc Epoetin (Eritropoyetin) Product Portfolio
- 4.8.5 Hospira Inc Recent Developments
- 4.9 Epoetin
- 4.9.1 Epoetin Company Information
- 4.9.2 Epoetin Business Overview
- 4.9.3 Epoetin Epoetin (Eritropoyetin) Sales, Revenue and Gross Margin (2021-2026)
- 4.9.4 Epoetin Epoetin (Eritropoyetin) Product Portfolio
- 4.9.5 Epoetin Recent Developments
- 4.10 Celltrion, Inc
- 4.10.1 Celltrion, Inc Company Information
- 4.10.2 Celltrion, Inc Business Overview
- 4.10.3 Celltrion, Inc Epoetin (Eritropoyetin) Sales, Revenue and Gross Margin (2021-2026)
- 4.10.4 Celltrion, Inc Epoetin (Eritropoyetin) Product Portfolio
- 4.10.5 Celltrion, Inc Recent Developments
- 4.11 Biocon
- 4.11.1 Biocon Company Information
- 4.11.2 Biocon Business Overview
- 4.11.3 Biocon Epoetin (Eritropoyetin) Sales, Revenue and Gross Margin (2021-2026)
- 4.11.4 Biocon Epoetin (Eritropoyetin) Product Portfolio
- 4.11.5 Biocon Recent Developments
- 4.12 Abcam
- 4.12.1 Abcam Company Information
- 4.12.2 Abcam Business Overview
- 4.12.3 Abcam Epoetin (Eritropoyetin) Sales, Revenue and Gross Margin (2021-2026)
- 4.12.4 Abcam Epoetin (Eritropoyetin) Product Portfolio
- 4.12.5 Abcam Recent Developments
5 Global Epoetin (Eritropoyetin) Market Scenario by Region
- 5.1 Global Epoetin (Eritropoyetin) Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Epoetin (Eritropoyetin) Sales by Region: 2021-2032
- 5.2.1 Global Epoetin (Eritropoyetin) Sales by Region: 2021-2026
- 5.2.2 Global Epoetin (Eritropoyetin) Sales by Region: 2027-2032
- 5.3 Global Epoetin (Eritropoyetin) Revenue by Region: 2021-2032
- 5.3.1 Global Epoetin (Eritropoyetin) Revenue by Region: 2021-2026
- 5.3.2 Global Epoetin (Eritropoyetin) Revenue by Region: 2027-2032
- 5.4 North America Epoetin (Eritropoyetin) Market Facts & Figures by Country
- 5.4.1 North America Epoetin (Eritropoyetin) Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Epoetin (Eritropoyetin) Sales by Country (2021-2032)
- 5.4.3 North America Epoetin (Eritropoyetin) Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.4.6 Mexico
- 5.5 Europe Epoetin (Eritropoyetin) Market Facts & Figures by Country
- 5.5.1 Europe Epoetin (Eritropoyetin) Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Epoetin (Eritropoyetin) Sales by Country (2021-2032)
- 5.5.3 Europe Epoetin (Eritropoyetin) Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Russia
- 5.5.9 Spain
- 5.5.10 Netherlands
- 5.5.11 Switzerland
- 5.5.12 Sweden
- 5.5.13 Poland
- 5.6 Asia Pacific Epoetin (Eritropoyetin) Market Facts & Figures by Country
- 5.6.1 Asia Pacific Epoetin (Eritropoyetin) Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Epoetin (Eritropoyetin) Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Epoetin (Eritropoyetin) Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Epoetin (Eritropoyetin) Market Facts & Figures by Country
- 5.7.1 South America Epoetin (Eritropoyetin) Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Epoetin (Eritropoyetin) Sales by Country (2021-2032)
- 5.7.3 South America Epoetin (Eritropoyetin) Revenue by Country (2021-2032)
- 5.7.4 Brazil
- 5.7.5 Argentina
- 5.7.6 Chile
- 5.8 Middle East and Africa Epoetin (Eritropoyetin) Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Epoetin (Eritropoyetin) Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Epoetin (Eritropoyetin) Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Epoetin (Eritropoyetin) Revenue by Country (2021-2032)
- 5.8.4 Egypt
- 5.8.5 South Africa
- 5.8.6 Israel
- 5.8.7 Türkiye
- 5.8.8 GCC Countries
6 Segment by Type
- 6.1 Global Epoetin (Eritropoyetin) Sales by Type (2021-2032)
- 6.1.1 Global Epoetin (Eritropoyetin) Sales by Type (2021-2032) & (units)
- 6.1.2 Global Epoetin (Eritropoyetin) Sales Market Share by Type (2021-2032)
- 6.2 Global Epoetin (Eritropoyetin) Revenue by Type (2021-2032)
- 6.2.1 Global Epoetin (Eritropoyetin) Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Epoetin (Eritropoyetin) Revenue Market Share by Type (2021-2032)
- 6.3 Global Epoetin (Eritropoyetin) Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Epoetin (Eritropoyetin) Sales by Application (2021-2032)
- 7.1.1 Global Epoetin (Eritropoyetin) Sales by Application (2021-2032) & (units)
- 7.1.2 Global Epoetin (Eritropoyetin) Sales Market Share by Application (2021-2032)
- 7.2 Global Epoetin (Eritropoyetin) Revenue by Application (2021-2032)
- 7.2.1 Global Epoetin (Eritropoyetin) Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Epoetin (Eritropoyetin) Revenue Market Share by Application (2021-2032)
- 7.3 Global Epoetin (Eritropoyetin) Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Epoetin (Eritropoyetin) Value Chain Analysis
- 8.1.1 Epoetin (Eritropoyetin) Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Epoetin (Eritropoyetin) Production Mode & Process
- 8.2 Epoetin (Eritropoyetin) Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Epoetin (Eritropoyetin) Distributors
- 8.2.3 Epoetin (Eritropoyetin) Customers
9 Global Epoetin (Eritropoyetin) Analyzing Market Dynamics
- 9.1 Epoetin (Eritropoyetin) Industry Trends
- 9.2 Epoetin (Eritropoyetin) Industry Drivers
- 9.3 Epoetin (Eritropoyetin) Industry Opportunities and Challenges
- 9.4 Epoetin (Eritropoyetin) Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst